0000899243-23-005687.txt : 20230221
0000899243-23-005687.hdr.sgml : 20230221
20230221163034
ACCESSION NUMBER: 0000899243-23-005687
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220816
FILED AS OF DATE: 20230221
DATE AS OF CHANGE: 20230221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Howze Yalonda
CENTRAL INDEX KEY: 0001828153
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39615
FILM NUMBER: 23648658
MAIL ADDRESS:
STREET 1: C/O CODIAK BIOSCIENCES, INC.
STREET 2: 35 CAMBRIDGEPARK DRIVE, SUITE 500
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Codiak BioSciences, Inc.
CENTRAL INDEX KEY: 0001659352
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 CAMBRIDGEPARK DRIVE
STREET 2: SUITE 500
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
BUSINESS PHONE: 617-949-4100
MAIL ADDRESS:
STREET 1: 35 CAMBRIDGEPARK DRIVE
STREET 2: SUITE 500
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
FORMER COMPANY:
FORMER CONFORMED NAME: Codiak Biosciences, Inc.
DATE OF NAME CHANGE: 20151125
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-08-16
0
0001659352
Codiak BioSciences, Inc.
CDAK
0001828153
Howze Yalonda
C/O CODIAK BIOSCIENCES, INC.
35 CAMBRIDGEPARK DRIVE, SUITE 500
CAMBRIDGE
MA
02140
0
1
0
0
See Remarks
Common Stock
2022-08-16
4
M
0
4857
A
7345
D
Common Stock
2022-08-17
4
S
0
1512
2.2135
D
5833
D
Common Stock
2023-02-16
4
M
0
4856
A
10689
D
Common Stock
2023-02-17
4
S
0
1603
0.5929
D
9086
D
Restricted Stock Units
2022-08-16
4
M
0
4857
0.00
D
Common Stock
4857
14568
D
Restricted Stock Units
2023-02-16
4
M
0
4856
0.00
D
Common Stock
4856
9712
D
Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of RSUs pursuant to a "sell to cover" provision included in the RSU Agreement.
Each RSU represents a contingent right to receive one share of common stock.
On February 16, 2022, the reporting person was granted 19,425 RSUs, vesting in four equal installments every six months beginning on the six month anniversary of the grant date.
Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary
/s/ Yalonda Howze
2023-02-21